NASDAQ:EVOK Evoke Pharma - EVOK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.76 +0.13 (+4.94%) (As of 03/23/2023 11:13 AM ET) Add Compare Share Share Today's Range$2.63▼$2.8850-Day Range$2.63▼$5.7552-Week Range$1.37▼$16.80Volume11,598 shsAverage Volume36,535 shsMarket Capitalization$9.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Evoke Pharma (NASDAQ:EVOK) StockEvoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.Read More Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EVOK Stock News HeadlinesMarch 23, 2023 | finance.yahoo.comEvoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023March 22, 2023 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 23, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 22, 2023 | benzinga.comGlow Launches New Brand Identity to Underscore Its High-Performance, Technology-Driven Portfolio of Natural IngredientsMarch 21, 2023 | marketwatch.comEvoke Pharma Shares Up 4.8% on Higher 4Q SalesMarch 21, 2023 | finance.yahoo.comEvoke Pharma Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 21, 2023 | marketwatch.comGastroenterology Market: The Growing Trend 2030March 20, 2023 | marketwatch.com2023 Diabetic Gastroparesis Market Size, Trends, Growth, Share, Business Analysis, Key Players, Merger, Statistics, Competitive LandscapeMarch 23, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 20, 2023 | markets.businessinsider.comEvoke Pharma is about to announce its earnings — here's what to expectMarch 17, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)March 15, 2023 | finance.yahoo.comEvoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023February 23, 2023 | marketwatch.comDiabetic Gastroparesis Market Future Trends Demand 2023, and Forecast to 2028February 22, 2023 | marketwatch.comGastroenterology Market International Business Analysis, Development Outlook and Regional Strategies 2028February 21, 2023 | finance.yahoo.comEvoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary SessionFebruary 18, 2023 | marketwatch.comGastroenterology Market 2023 : Incredible Possibilities, Growth Analysis and Forecast To 2028January 30, 2023 | msn.comEvoke stock rises on filing of dismissal in nasal spray Gimoti's patent infringement caseJanuary 30, 2023 | finance.yahoo.comEvoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against GimotiJanuary 18, 2023 | finance.yahoo.comEvoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023January 5, 2023 | forbes.comEvoke PharmaDecember 14, 2022 | msn.comEvoke Pharma's Return On Capital Employed InsightsDecember 7, 2022 | finance.yahoo.comUSPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe GastroparesisNovember 30, 2022 | finance.yahoo.comEvoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®November 12, 2022 | finance.yahoo.comEvoke Pharma Third Quarter 2022 Earnings: Beats ExpectationsNovember 10, 2022 | seekingalpha.comEvoke Pharma, Inc. (EVOK) Q3 2022 Results - Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comEvoke Pharma Reports Record Third Quarter 2022 Financial ResultsNovember 8, 2022 | msn.comEarnings Preview: Evoke PharmaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EVOK Company Calendar Last Earnings3/21/2023Today3/22/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.7506) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,540,000.00 Net Margins-391.75% Pretax Margin-390.45% Return on Equity-178.36% Return on Assets-68.51% Debt Debt-to-Equity Ratio0.90 Current Ratio7.06 Quick Ratio6.94 Sales & Book Value Annual Sales$1.62 million Price / Sales5.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book2.01Miscellaneous Outstanding Shares3,340,000Free Float3,000,000Market Cap$8.78 million OptionableNot Optionable Beta0.41 Key ExecutivesDavid A. GonyerChief Executive Officer & DirectorMatthew J. D'OnofrioPresident, Chief Operating Officer & SecretaryMarilyn R. CarlsonChief Medical OfficerKey CompetitorsContext TherapeuticsNASDAQ:CNTXGraybug VisionNASDAQ:GRAYAlimera SciencesNASDAQ:ALIMHillstream BioPharmaNASDAQ:HILSSonnet BioTherapeuticsNASDAQ:SONNView All Competitors EVOK Stock - Frequently Asked Questions How have EVOK shares performed in 2023? Evoke Pharma's stock was trading at $2.68 on January 1st, 2023. Since then, EVOK stock has decreased by 1.9% and is now trading at $2.63. View the best growth stocks for 2023 here. Are investors shorting Evoke Pharma? Evoke Pharma saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 26,100 shares, an increase of 54.4% from the February 13th total of 16,900 shares. Based on an average daily volume of 41,700 shares, the short-interest ratio is currently 0.6 days. Approximately 0.8% of the company's stock are sold short. View Evoke Pharma's Short Interest. When is Evoke Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our EVOK earnings forecast. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) posted its earnings results on Tuesday, March, 21st. The specialty pharmaceutical company reported ($0.53) earnings per share for the quarter. The specialty pharmaceutical company earned $0.80 million during the quarter. Evoke Pharma had a negative net margin of 391.75% and a negative trailing twelve-month return on equity of 178.36%. When did Evoke Pharma's stock split? Evoke Pharma's stock reverse split on the morning of Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY). What is Evoke Pharma's stock symbol? Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK." Who are Evoke Pharma's major shareholders? Evoke Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Gonyer and Matthew J D'onofrio. View institutional ownership trends. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evoke Pharma's stock price today? One share of EVOK stock can currently be purchased for approximately $2.63. How much money does Evoke Pharma make? Evoke Pharma (NASDAQ:EVOK) has a market capitalization of $8.78 million and generates $1.62 million in revenue each year. The specialty pharmaceutical company earns $-8,540,000.00 in net income (profit) each year or ($2.7506) on an earnings per share basis. How can I contact Evoke Pharma? Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The official website for the company is www.evokepharma.com. The specialty pharmaceutical company can be reached via phone at (858) 345-1494 or via email at tbui@theruthgroup.com. This page (NASDAQ:EVOK) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.